Transition and Separation from Employment Clause Samples
Transition and Separation from Employment. The Parties agree that Executive's initial transition from his role as Executive Vice-President, Chief Financial Officer and Treasurer of First Charter and the Bank shall start on May 17, 2007 (the "Transition Date"). Despite Executive's transition from his positions, the Parties agree that following Executive's signing of this Agreement, and provided all conditions of this Agreement are met by Executive, after the Transition Date, Executive shall voluntarily relinquish his duties and responsibilities as Chief Financial Officer and Treasurer but continue to be employed by First Charter as Executive Vice-President for a period through August 17, 2007 (the "Separation Date"), upon which Executive's official employment with First Charter, the Bank and/or their related subsidiaries in all capacities shall end. The Parties further agree that the period from the May 17, 2007 Transition Date through the August 17, 2007 Separation Date shall collectively be defined and referred to as the "Transition Period". The Parties agree that during the Transition Period, Executive will work and reasonably cooperate with First Charter and its officers and employees as needed and requested in providing advice and assistance regarding the transition of his position responsibilities, including but not limited to work on the completion of financial and other records and other specific project assignments and transition issues that may arise regarding subject matters that are within the current scope of his job duties, responsibilities and expertise. In addition, during such period, First Charter agrees to coordinate with Executive regarding work scheduling such that his transition assistance does not unreasonably interfere with any search for other employment. The Parties expressly acknowledge and agree that notwithstanding the terms of Executive's April 13, 2005 Employment Agreement with First Charter (the "Employment Agreement"), this Agreement is and will be enforceable and First Charter will be in compliance with this provision 1 provided Executive is paid his applicable regular compensation and benefits as modified in provision 3 below through the Separation Date, whether or not he is actually required to perform complete, full-time services for First Charter during the Transition Period. In addition, except for Executive's opportunity to obtain continuation medical coverage as allowed by and pursuant to COBRA or as otherwise set forth in provisions 3 and 4 below, Executive'...
Transition and Separation from Employment. Your separation from employment will occur on the earlier of March 31, 2022 or such other date that is mutually agreed between the Company and you (“Separation Date”). The period between the date of this letter agreement and the Separation Date is referred to in this letter agreement as your “Transition Period.” On your Separation Date, you will relinquish any and all positions that you have held with the Company and you will not be considered a Company employee for any purpose after that date.
Transition and Separation from Employment. Effective as of October 1, 2025 (“Transition Date”), Employee shall step down from Employee’s position as Chief Financial Officer of Option Care Health, Inc. (“OPCH”) and his officer positions with OPCH and Option Care and shall be relieved of all duties with respect to OPCH, Option Care and their affiliates, except as otherwise set forth herein. For the period between the Transition Date and March 31, 2026 (except as otherwise set forth below, the “Termination Date,” and such period, the “Transition Period”), Employee shall be considered a non-executive employee of Option Care, serving as “Special Advisor” to the Chief Executive Officer of Option Care, during which period Employee’s duties shall include consulting on transition matters relating to Employee’s prior duties to Option Care as well as other duties requested by the Chief Executive Officer of Option Care. The parties expect that Employee’s duties during the Transition Period generally shall require Employee to provide services in excess of 33% of the average level of services performed by Employee during Employee’s employment with the Company prior to the Transition Date. Effective on the Termination Date, unless otherwise agreed to by the parties, Employee shall be deemed to have resigned, without any further action by Employee, from any and all positions that Employee holds with Option Care, OPCH, and any of their affiliates. For the avoidance of doubt, E▇▇▇▇▇▇▇’s transition to the role of Special Advisor on the Transition Date, and the related changes to Employee’s compensation and benefits as described herein, shall not constitute “Good Reason” for purposes of the Option Care Health, Inc. Amended and Restated Executive Severance Plan (the “Severance Plan”), and Employee shall not be entitled to any benefits under the Severance Plan or the Employment Agreement, dated as of October 13, 2015, between Walgreens Infusion Services, Inc. and Employee (the “Employment Agreement”) in connection with the termination of Employee’s employment as contemplated herein.
Transition and Separation from Employment. Employee’s employment with the Company in his role as the Chief Financial Officer shall continue until the earlier of (a) March 31, 2024 or such later date as the Company requests for you to continue in your role as Chief Financial Officer, but such later date shall not be after June 30, 2024, or such later date as the Parties may mutually agree to in writing, or (b) if the Company appoints your successor as Chief Financial Officer prior to March 31, 2024, such date that the Company determines that the transition of your knowledge and duties as Chief Financial Officer to such successor Chief Financial Officer is complete (such date, the “CFO Transition Date”), which shall be no later than the Separation Date. You shall remain an employee through earlier of (i) your termination of employment, or (ii) June 30, 2024 or such later date as the Parties may mutually agree in writing. You agree to travel to the Company’s Boston headquarters consistent with past practice as well as other customary and ordinary business travel. You agree to continue to utilize your best efforts in the performance of your duties as the Company’s Chief Financial Officer through March 31, 2024, and for the period from April 1, 2024 through the CFO Transition Date if after March 31, 2024, you will continue to use your best efforts in the performance of your duties as reasonably assigned by the Company. The actual date of the termination of your employment is herein referred to as the “Separation Date.” Consistent with past practice, you will be allowed to enter into advisory agreements with other companies which do not compete with the Company upon approval by the Company which will not be unreasonably withheld. You acknowledge and agree that you were provided a copy of this Agreement on October 23, 2023 (the “Notification Date”). This Agreement is intended to provide you with additional benefits and compensation than you would have otherwise been entitled. The period between the Notification Date and Separation Date is herein referred to as the “Transition Period.”
Transition and Separation from Employment. Effective as of January 31, 2023 (the “Transition Date”), you will resign from your position as Chief Technology Officer of the Company and will be relieved of all duties, except as otherwise set forth herein. For the entire period between the Transition Date and March 30, 2023 (the “Separation Date,” and such period the “Transition Period”) you will be considered a non-executive “Advisor” to the Company, during which your duties will be limited to consulting on transition matters relating to your separation from the Company. By no later than the Separation Date, the Company will provide you a sum that represents all of your earned but unpaid compensation (the “Final Pay”). You are not required to sign this Agreement to receive your Final Pay.
Transition and Separation from Employment. The Parties agree that Executive's active involvement as Senior Vice President, Strategic Planning and Corporate Development with the Company shall end on Tuesday, March 18, 2003, after which Executive shall continue to be employed by the Company for a period through, and Executive's official employment with the Company shall end, effective March 31, 2003. The Parties agree that prior to Executive's separation from employment on March 31, 2003, Executive will reasonably cooperate with the Company in the transition of his position responsibilities on an as-needed basis during regular business hours. Moreover, during the period April 1, 2003 through June 30, 2003, Executive agrees to consult with the Company on a limited, as-needed basis concerning post-transition issues that may arise with respect to subject matters that are within the current scope of his job duties and responsibilities; provided that such consulting services shall not exceed more than twenty (20) hours per week during regular business hours. Except for Executive's opportunity to obtain continuation medical coverage as allowed by and pursuant to COBRA after March 31, 2003, Executive's ongoing rights to any accrued, vested benefits or as otherwise set forth below, Executive's rights to his regular benefits shall cease effective March 31, 2003. The Parties further acknowledge and agree that except for the confidentiality, non-compete, return of documents and other post-employment obligations of Executive under the Change in Control Agreement signed by Executive on October 1, 1997 (the "Change in Control Agreement"), which obligations shall continue to remain in full force and effect, the Change in Control Agreement shall be terminated, effective March 31, 2003.
Transition and Separation from Employment. ▇▇. ▇▇▇▇▇▇▇▇▇ is currently a director, President and Chief Executive Officer of the Company. ▇▇. ▇▇▇▇▇▇▇▇▇ and the Company agree that it is in the best interest of ▇▇. ▇▇▇▇▇▇▇▇▇ and the Company for ▇▇. ▇▇▇▇▇▇▇▇▇’▇ employment relationship with the Company to transition under the terms set forth below, and end as of October 1, 2020 (hereinafter the “Separation Date”):
Transition and Separation from Employment. Effective as of December 7, 2023 (“Transition Date”) and subject to Section 2 below, Employee shall step down from Employee’s position as Chief Commercial Officer of Option Care Health, Inc. (“OPCH”) and his officer positions with OPCH and Option Care and shall be relieved of all duties with respect to OPCH, Option Care and their affiliates, except as otherwise set forth herein. For the period between the Transition Date and March 31, 2024 (“Termination Date,” and such period, the “Transition Period”), Employee shall be considered a non-executive employee of Option Care, serving as “Special Advisor” to the Chief Executive Officer of Option Care, during which period Employee’s duties shall be limited to consulting on transition matters relating to Employee’s prior duties to Option Care. Subject to Section 2 below, as of the Termination Date, Employee’s employment with Option Care will be terminated by Option Care without Cause.
Transition and Separation from Employment. Effective as of September 29, 2022 (the “Transition Date”), you have resigned from your position as Chief Marketing Officer of the Company and have been relieved of all duties, except as otherwise set forth herein. For the entire period between the Transition Date and December 30, 2022 (the “Separation Date,” and such period the “Transition Period”) you will be considered a non-executive “Advisor” to the Company and will not be required to work in excess of five (5) hours a week for the Company, during which your duties will be limited to consulting on transition matters relating to your separation from the Company. By no later than the Separation Date, the Company will provide you a sum that represents all of your earned but unpaid compensation (the “Final Pay”). You are not required to sign this Agreement to receive your Final Pay.
Transition and Separation from Employment. Dear ▇▇▇: This letter agreement (the “Agreement and Release” or the “Agreement”) between you and Knight Capital Americas LLC, a Delaware limited liability company, having its principal place of business at ▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ and Knight Capital Group, Inc., a Delaware corporation (hereinafter collectively referred to with Knight Capital Americas LLC as “Knight” or the “Company”), confirms our understanding and agreement with respect to your termination of employment with the Company, which is subject to the closing of the sale of the U.S. assets of the Company’s Institutional and Fixed Income Sales and Trading business (“KFI”) to ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ & Company, Incorporated (“Stifel”) and the release of the U.K. employees of KFI to Stifel, as follows: